<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00581477</url>
  </required_header>
  <id_info>
    <org_study_id>030750</org_study_id>
    <secondary_id>HL056693</secondary_id>
    <nct_id>NCT00581477</nct_id>
  </id_info>
  <brief_title>Treatment of Orthostatic Hypotension</brief_title>
  <official_title>Treatment of Hypotensive Patients Having a Unique Pattern of Autonomic Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to try different medications in patients with low blood pressure
      and other problems with their involuntary (autonomic) nervous system. The pharmacological
      trials in this study will perhaps lead to more effective treatment. This study consists of
      single dose trials, dose selection trials, 5-day trials and chronic (approximately 2 months)
      trials.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We see many patients at the Autonomic Dysfunction Center who can be given a fairly definitive
      diagnosis, e.g., Orthostatic Intolerance, Pure Autonomic Failure, Multiple System Atrophy,
      and Baroreflex Failure. However, some patients present with a unique constellation of
      symptoms of autonomic dysfunction so that they do not fit into a diagnostic category. We
      hypothesize that a genetic cause exists in some of these patients. We further propose that
      our comprehensive evaluation of these patients will provide us with information on the
      pathophysiology of their condition and assist us in optimizing their treatment.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in blood pressure with standing</measure>
    <time_frame>following 5 days of medication</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>length of time subject is able to stand</measure>
    <time_frame>following 5 days of medication</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Autonomic Nervous System Diseases</condition>
  <condition>Orthostatic Hypotension</condition>
  <condition>Dopamine Beta-Hydroxylase Deficiency</condition>
  <condition>Orthostatic Intolerance</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>droxidopa</intervention_name>
    <description>up to 300mg four times daily</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>same frequency as experimental medication</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alpha-methyldopa</intervention_name>
    <description>up to 250mg two times daily</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Aldomet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carbidopa</intervention_name>
    <description>up to 25mg four times daily</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Lodosyn</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metyrosine</intervention_name>
    <description>up to 1000mg three times daily</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Demser</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levodopa</intervention_name>
    <description>up to 250mg three times daily</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Larodopa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atomoxetine</intervention_name>
    <description>up to 40mg twice daily</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Strattera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metoclopramide</intervention_name>
    <description>up to 10mg four times daily</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Reglan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with severe orthostatic hypotension and other autonomic symptoms who do not
             meet criteria for one of our standard diagnoses

          -  non-smokers

          -  drug-free

          -  able to give informed consent

          -  free of pulmonary, renal, hematopoietic, hepatic and cardiac disease

        Exclusion Criteria:

          -  medications affecting the autonomic nervous system

          -  any chronic illness (cardiac, pulmonary, endocrine, gastrointestinal, rheumatologic)

          -  anemia (Hct &lt; 30)

          -  women of childbearing age who are pregnant or nursing

          -  smokers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Robertson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mc.vanderbilt.edu/root/vumc.php?site=adc</url>
    <description>Autonomic Dysfunction Center Website</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2007</study_first_submitted>
  <study_first_submitted_qc>December 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 27, 2007</study_first_posted>
  <last_update_submitted>March 26, 2018</last_update_submitted>
  <last_update_submitted_qc>March 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Emily M. Garland</investigator_full_name>
    <investigator_title>Research Associate Professor</investigator_title>
  </responsible_party>
  <keyword>autonomic nervous system diseases</keyword>
  <keyword>blood pressure</keyword>
  <keyword>congenital</keyword>
  <keyword>orthostasis</keyword>
  <keyword>catecholamines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypotension</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Hypotension, Orthostatic</mesh_term>
    <mesh_term>Orthostatic Intolerance</mesh_term>
    <mesh_term>Autonomic Nervous System Diseases</mesh_term>
    <mesh_term>Primary Dysautonomias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Droxidopa</mesh_term>
    <mesh_term>Metoclopramide</mesh_term>
    <mesh_term>Atomoxetine Hydrochloride</mesh_term>
    <mesh_term>Methyldopa</mesh_term>
    <mesh_term>alpha-Methyltyrosine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

